Takeda terminated its eight-year neuroscience partnership with Denali Therapeutics, returning full global rights to DNL593 to Denali. Takeda said the decision was driven by strategic considerations and not related to the therapy’s efficacy or safety, while the companies’ filings pointed to broader restructuring and cost-savings efforts. Takeda originally paid $150 million in 2018, combining upfront cash with an equity stake, to co-develop and co-commercialize up to three neurodegenerative candidates using Denali’s antibody transport vehicle (ATV) technology designed to cross the blood-brain barrier. Denali’s CEO said the company plans to report results from the ongoing Phase 1/2 trial by the end of 2026 and intends to advance DNL593 independently. The return of rights shifts the development and commercialization strategy back to the original developer. For the biotech sector, the move is another example of how internal portfolio reshaping can accelerate asset reassignments, changing who carries the next clinical and regulatory milestones.